 This research suggests that a purified trichoderma viride l-aspiraginase could potentially be used as a potential candidate for future applications in medicine as an anti-cancer medication. The l-aspiraginase was shown to have strong anti-proliferative activity against the HEPG2 cell line with an IC50 of 21.2 GmL, which was higher than that observed for the MCF7 cell line, IC5034.2 GmL. Additionally, the l-aspiraginase was found to reduce the levels of liver and kidney injury markers associated with diethyl nitrosamine, DINA, intoxication. Furthermore, the l-aspiraginase was also found to improve the levels of these biomarkers to near normal levels in the treated DINA intoxicated group. These findings suggest that the l-aspiraginase may be useful in treating patients with liver cancer. This article was authored by DINA H. Elgonamy, Sanaa Ali, Rehab M. Abdelmighi, and others.